Browsing by author "Larkin, James"
Now showing items 61-74 of 74
-
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Haanen, J; Ernstoff, M; Wang, Y; Menzies, A; Puzanov, I; et al. (BMJ PUBLISHING GROUP, 2020-01-01)Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint ... -
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Valpione, S; Carlino, MS; Mangana, J; Mooradian, MJ; McArthur, G; et al. (ELSEVIER SCI LTD, 2018-03-01)BACKGROUND: Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that ... -
Renal cell carcinoma.
Hsieh, JJ; Purdue, MP; Signoretti, S; Swanton, C; Albiges, L; et al. (2017-03-09)Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) ... -
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
Bowyer, S; Prithviraj, P; Lorigan, P; Larkin, J; McArthur, G; et al. (2017-04) -
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
Weber, JS; Hodi, FS; Wolchok, JD; Topalian, SL; Schadendorf, D; et al. (2017-03)Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and describe the management of adverse events (AEs) using established safety guidelines. ... -
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.
Rothermundt, C; von Rappard, J; Eisen, T; Escudier, B; Grünwald, V; et al. (2017-04)Background Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim was to investigate the approach for the ... -
SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy.
Higham, CE; Olsson-Brown, A; Carroll, P; Cooksley, T; Larkin, J; et al. (BIOSCIENTIFICA LTD, 2018-07-01)Immunotherapy treatment with checkpoint inhibitors (CPI) (CTLA-4 and PD-1 inhibitors) significantly improves survival in a number of cancers. Treatment can be limited by immune-mediated adverse effects including endocrinopathies ... -
Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma.
Scherrer, E; Rau, R; Lorenzi, M; Shui, I; Townson, S; et al. (FUTURE MEDICINE LTD, 2021-03-30)Aim: Summarize the literature assessing biomarkers in predicting efficacy of anti-PD-1 therapy for patients with high-risk unresectable or metastatic melanoma. Materials & methods: Relevant studies were identified via a ... -
Systemic treatment of advanced papillary renal cell carcinoma: Where next?
Turajlic, S; Larkin, J (2016-12) -
"Tell me what is 'better'!" How medical students experience feedback, through the lens of self-regulatory learning.
Spooner, M; Larkin, J; Liew, SC; Jaafar, MH; McConkey, S; et al. (BMC, 2023-11-22)INTRODUCTION: While feedback aims to support learning, students frequently struggle to use it. In studying feedback responses there is a gap in explaining them in relation to learning theory. This study explores how feedback ... -
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Hodi, FS; Wolchok, JD; Schadendorf, D; Larkin, J; Long, GV; et al. (AMER ASSOC CANCER RESEARCH, 2021-10-01)Outcomes for patients with melanoma have improved over the past decade as a result of the development and FDA approval of immunotherapies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and ... -
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.
Regan, MM; Mantia, CM; Werner, L; Tarhini, AA; Larkin, J; et al. (BMJ PUBLISHING GROUP, 2021-11-01)BACKGROUND: Treatment-free survival (TFS) characterizes disease control after discontinuation of immune checkpoint inhibitors (ICIs) until subsequent therapy or death. We previously evaluated TFS in a pooled analysis of ... -
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.
Regan, MM; Werner, L; Rao, S; Gupte-Singh, K; Hodi, FS; et al. (AMER SOC CLINICAL ONCOLOGY, 2019-12-10)PURPOSE: Outcome measures that comprehensively capture attributes of immuno-oncology agents, including prolonged treatment-free time and persistent treatment-related adverse events (TRAEs), are needed to complement ... -
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
Choueiri, TK; Motzer, RJ; Rini, BI; Haanen, J; Campbell, MT; et al. (2020-08)Background The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma ...